יחס חוב לטווח קצר להון עצמי: Voyager Therapeutics (VYGR)

The market valuation dynamics for Voyager Therapeutics (VYGR) demonstrate a figure of 0.04, while the business faces international patenting risks and raw material supply chain complexities. Steady interest in cutting-edge treatments makes the company a resilient defensive asset with little dependence on general economic trends. However, success relies on partnerships with industry behemoths, which creates the risk of project loss.

This metric measures the share of short-term liabilities within the equity structure, determining the company's liquidity and financial stability over a one-year horizon. Investors analyze the ratio of short-term debt to equity to assess refinancing risks during periods of rate volatility. A decrease in this metric confirms solvency, which is critical for Voyager Therapeutics (VYGR) as it scales AI-driven capsid screening. The automation of laboratory tests requires stable funding without excessive pressure from short-term loans.